TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: long-term compliance with HT
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: VAS score in the first 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue anaesthetic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Secondary postoperative effects
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in CD34(+) cells in PB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of CD34(+) cells expressing CXCR4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma level of SDF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal lavage EPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum EPO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ODI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Soft palate angulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tongue height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by Short Form 36 questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rim area correlation with visual field indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rim volume correlation with visual field indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inflammatory spinal lesions per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sore throat severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of delivery for tobacco-dependence treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of anaemia (Hb <11 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Y-BOCS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-adherence to injury prevention guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea scores on a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-8 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in GFR of the affected kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary RBP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum transaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: combined end-point (hospital admissions and death)
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3 gastrointestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 genitourinary toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical site infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: real-life functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: symptom load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Terumo radial band removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores of 0 at 1 hour after band placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sEMG signal amplitude of the fibularis longus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chalder fatigue scale scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Physiological function (PF) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: General health (GH) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Na change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative dysuria
Endpoint domain: Adverse events/effects
Primary endpoint: cardiovascular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reinfarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular accidents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-risk plaque prevalence in patients with NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seattle Angina Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Seattle Angina Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Quality of life
Primary endpoint: CMR mid-ventricular MPRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage change in bone mineral density (BMD) at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in bone mineral density (BMD) at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in bone mineral density (BMD) at total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: airway symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequencies of minor adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Blood platelet responsiveness to ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall failure rate of CQ and SP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak systolic velocities of longitudinal contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TWA level above the 75th percentile during maximum heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of life-threatening arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total effective rate of hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in hand spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Inappropriate ATP
Endpoint domain: Adverse events/effects
Primary endpoint: Inappropriate shock therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Fibronectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactulose/mannitol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral vascular complications
Endpoint domain: Adverse events/effects
Primary endpoint: Elective revascularization procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in RV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Methodological Quality (MQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Ethical Quality (EQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Estimated median survival times
Endpoint domain: Mortality/survival
Primary endpoint: Estimated median patency durations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major macrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Major LARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial microvascular perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of MVS after 4-week therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: usage volume of peanut butter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slower rate of global deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gradual improvement in global functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of deliveries within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proportion of regional analgesia requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Basal LPS‐induced cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of cesarean delivery
Endpoint domain: Mortality/survival
Primary endpoint: accuracy in assessing exact dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy in assessing exact effacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consistency in assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h cumulative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle-bone cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: isometric and isokinetic knee extension and flexion torques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hand dexterity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug reactions (ADR) incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative survival probability
Endpoint domain: Mortality/survival
Primary endpoint: Reduced cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Total protection against cholera
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of relapse
Endpoint domain: Mortality/survival
Primary endpoint: Performance at C2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower limb Fugl‐Meyer score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum LH and FSH concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T50 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality adjusted life years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: a-wave amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: b-wave amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in ODD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily steps walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric strength gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking performance (normal-pace walk-turn-walk)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue medications and consultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Emotional burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain scores during suctioning
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in Snellen line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discharge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up LDL-C level of < 100 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean time to void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Antibody production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS for pain-level scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: remission of sleep symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission of core symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine loss cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of disulfiram
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worsening of key symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FF level of suPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of severe OHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC mortality
Endpoint domain: Mortality/survival
Primary endpoint: Correct identification of toxic vial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KSS (Knee Society Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoglobin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine kinase increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periorbital ecchymosis
Endpoint domain: Adverse events/effects
Primary endpoint: subconjunctival ecchymosis
Endpoint domain: Adverse events/effects
Primary endpoint: edema
Endpoint domain: Adverse events/effects
Primary endpoint: GHb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: remission from the UHR state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: diet quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in total IS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in depressive symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IGA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite fingernail score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Epworth Sleepiness Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocardial visualisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular (LV) volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HA frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HA pain reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in ETDRS visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rested rating scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: shortened stage 2 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep and subcutaneous tissue outcomes
Primary endpoint: prolonged REM sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep and subcutaneous tissue outcomes
Primary endpoint: Overall AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AKI requiring RRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: carbon monoxide boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of MRONJ stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of periodic leg movements per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HADS depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cell-mediated immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recurrence rate of disease
Endpoint domain: Mortality/survival
Primary endpoint: occurrence rate of side‐effects of prednisone
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of positive CRMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of lactulose breath test level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of lactose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease of intensity of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total kidney volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of participants providing compressions of adequate depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compression rate compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of encounters with an antibiotic prescribed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of encounters with an inappropriate antibiotic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective sense of happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of deep venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ΔSOFA score on day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: age-corrected objective learning test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of procedure duration with MAP below predefined threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of hypotensive episodes per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delirium persistence at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean capillary glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: neonatal hyperbilirubinemia rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital cost savings
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Views on mental illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery beliefs
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight gain in adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pVo2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Nottingham Health Profile scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Y-BOCS decrease of at least 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rates for paroxetine and venlafaxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdural puncture headache incidence
Endpoint domain: Adverse events/effects
Primary endpoint: symptomatic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HFRDIS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction in self-reported hearing handicap
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing